



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Abbott Laboratories
c/o Polsinelli Shughart PC
Two Prudential Plaza
180 N. Stetson Ave.
Suite 4525
Chicago, IL 60601

In Re: Patent Term Extension
Application for
U.S. Patent No. RE42,462


MAILED
MAY - 9 2012

Dear Ms. Mueller:

In response to (i) the March 22, 2010 paper titled "Petition Under 37 CFR § 1.181 Requesting Reconsideration Of The Determination Of The Length Of The Patent Term Extension Under 37 CFR § 1.710 For US Patent No. 5,932,730," (ii) the March 22, 2010 paper titled "Petition To Stay Proceedings Regarding Patent Term Extension Application For US Patent No. 5,932,730 Under 37 CFR § 1.182," (iii) the March 22, 2010 paper titled "Response To Notice Of Final Determination And Requirement For Election," (iv) the May 19, 2011 paper titled "Petition To Lift Stay Of Proceedings Regarding Patent Term Extension Application For US Patent No. 5,932,730 Under 37 CFR § 1.182," (v) the June 18, 2011 paper titled "Petition To Apply Patent Term Extension To U.S. Patent No. RE42,462 Under 37 CFR §§ 1.182," and (vi) the April 11, 2012 paper titled "Supplemental Paper," please find enclosed a certificate under 35 U.S.C. § 156 extending the term of U.S. Patent No. RE42,462 for a period of 1,026 days.

While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). Patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542, which may be downloaded from FDA's Electronic Forms Download Website: <http://www.fda.gov/opacom/morechoices/fdaforms/default.html> (<http://www.fda.gov/opacom/morechoices/fdaforms/FDA-3542.pdf>).

Inquiries regarding this communication should be directed to Raul Tamayo by telephone at (571) 272-7728, or by e-mail at raul.tamayo@uspto.gov.



Mary C. Till
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

RE: LETAIRIS® (ambrisentan)
FDA Docket No.: FDA-2008-E-0103

Attention: Beverly Friedman